Expert Interview
A Second Look: Discussing CD20xCD3 Bispecifics in DLBCL, with a focus on glofitamab & Epcoritamab
Ticker(s): ABBV, RHHBYInstitution: Maryland Oncology Hematology
- Medical Oncologist with specialties in Hematology, Breast Cancer, Lymphoma & Chronic Leukemia, Multiple Myeloma, Lung & Thoracic Cancers; Directed the hematology/oncology fellowship training program at the Cleveland Clinic.
- Manages 50 patients with DLBCL.
- Extensive research expertise in the laboratory and clinical trials with the pharmaceutical industry and leading academic institutions.
How many DLBCL patients do you treat?
Added By: wilson_adminHow has your experience been with glofitamab or Epcoritamab
Added By: wilson_adminHow does this class affect your treatment algorithm
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
